Neutral impactStocks

SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?

Economic Times 55 min ago·20 Nov 2026, 4:47 am

SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Regal Entertainment & Consultants (REGAL).
  • Category: Stocks.

Why it matters

A routine update for Regal Entertainment & Consultants. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Economic Times.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.